|Dr. Shailini Singh was born and raised in India. After earning her undergraduate degree from Banaras Hindu University and her medical degree from the Medical School at Lady Hardinge Medical College, New Delhi, India, she proceeded to Canada in January 1968 to become an Obstetrician and Gynecologist. She received her FRCS(C) from there and moved to USA in 1975. She became the first Maternal Fetal Medicine fellow at Harvard Medical School and Joslin Diabetes Foundation in 1975. There she had the privilege to work with Dr. Priscilla White, who was the God mother to all pregnant diabetic patients.Dr. Singh did her second fellowship from the University of Colorado. Following which she stayed on for next 10 years as a faculty in the obstetrician / gynecology department at the University. In 1993-1994 she was a senior Fulbright Scholar to AIIMS, New Delhi India. During her tenure as a Fulbright Scholar she taught around the country as well as conducted research in the effects of Chronic Maternal Anemia on fetus at AIIMS, and Safdarjang Hospital, New Delhi. She is now a Professor at University of Buffalo, SUNY and Director of Fetal Ultrasound Diagnostic Center and is starting a new Center of Metabolic Syndrome center in Pregnancy at Kaleida Health Care. She also had some training in invasive prenatal diagnosis from University of Puericulture in Paris, France and also worked at King Faisal Medical Center in Riyadh, Saudi Arabia through Yale Medical School Saudi- US project.
For the last 7 years Dr. Shalini Singh has been working in Appalachia, (WV) where patients had insulin resistance leading to GDM and Type II diabetes due to maternal obesity, probably developed in Utero. Obstetrics complications of obese pregnant women are many like preeclampsia leading to low birth weight babies and prematurity. Improvement have been made in the outcome of these obese pregnant diabetics in spite of intrinsic over nutrition by strict control of blood sugars with special calorie and carbohydrate restricted diet, life style changes and oral medications that increase the sensitivity of endogenous insulin and /or insulin usage and treating even low grade hypertension measured by non invasive hemodynamic assessment. This has decreased and delayed the onset of preeclampsia which is a leading cause of preterm birth less than 37 weeks of gestational age in these women with cardio metabolic disease. As a Fulbright-Nehru scholar Dr. Singh would like to help set up this program at AIIMS, New Delhi. This will help improve the health of fetus in the womb of the mother and decreasing the incidence of small for gestational age babies who get programmed in Utero to develop metabolic syndrome as adults which is rampant in India.